Patents Represented by Attorney Raymond M. Speer

Find this attorney in the Justia Lawyer Directory

  • Antibiotic cyclopeptide fermentation product
    Patent number: 5202309
    Abstract: An antibiotic agent produced by the cultivation of Zalerion arboricola which is a cyclic lipopeptide with very high activity against human pathogens and of very low mammalian toxicity is described. Its production and isolation are also described.
    Type: Grant
    Filed: August 19, 1991
    Date of Patent: April 13, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Robert E. Schwartz, Jerrold M. Liesch, Raymond F. White, Otto D. Hensens, Henry Joshua, Dennis M. Schmatz
  • Process for producing antifungal fermentation products and compositions thereof
    Patent number: 5196327
    Abstract: A mixture of derivatives of 2-amino-3,4,5,14-tetrahydroxy-6-eicosenoic acid has been isolated from a culture medium after cultivation of microorganisms belonging to the genus Aspergillus. The compounds are useful as antifungal agents.
    Type: Grant
    Filed: May 8, 1991
    Date of Patent: March 23, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Maria B. Lopez, Richard L. Monaghan
  • 2-phenanthrenyl carbapenem intermediates
    Patent number: 5196529
    Abstract: Carbapenems of the formula ##STR1## are useful as intermediates to antibacterial agents.
    Type: Grant
    Filed: October 9, 1990
    Date of Patent: March 23, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Frank P. Dininno, Thomas N. Salzmann, Mark L. Greenlee
  • Antibiotic agent
    Patent number: 5194377
    Abstract: An antibiotic agent produced by the cultivation of Zalerion arboricola which is a cyclic lipopeptide with very high activity against human pathogens and of very low mammalian toxicity is described. Its production and isolation are also described.
    Type: Grant
    Filed: August 9, 1991
    Date of Patent: March 16, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Robert E. Schwartz, Raymond F. White
  • Methods for thrombolytic therapy
    Patent number: 5188830
    Abstract: Certain Factor XIIIa inhibitor compounds have been discovered which have been found to be useful in the lysis of blood clots and thus adaptable for administration in thrombolytic therapy either alone or together with plasminogen activator.
    Type: Grant
    Filed: April 2, 1990
    Date of Patent: February 23, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Joseph G. Atkinson, David A. Claremon, John J. Baldwin, Paul A. Friedman, David C. Remy, Andrew M. Stern
  • Methods for thrombolytic therapy
    Patent number: 5185149
    Abstract: Certain Factor XIIIa inhibitor compounds have been discovered which have been found to be useful in the lysis of blood clots and thus adaptable for administration in thrombolytic therapy either alone or together with plasminogen activator.
    Type: Grant
    Filed: April 2, 1990
    Date of Patent: February 9, 1993
    Assignee: Merck & Co., Inc.
    Inventors: John J. Baldwin, Paul A. Friedman, Andrew M. Stern
  • Spirocyclic 6-amido-carbapenems and azetidinones
    Patent number: 5183887
    Abstract: New antibacterial spirocyclic 6-amido carbapenems of the structural formulas: ##STR1## wherein R.sup.1 is hydrogen, C.sub.1-8 substituted or unsubstituted alkyl, or C.sub.6-10 substituted or unsubstituted aryl; R.sup.5 is hydrogen or a protecting group for alcohol; R.sup.6 is hydrogen or a protecting group for amido nitrogen; R.sup.7 is hydrogen or a protecting group for amido nitrogen; and R.sup.8 is hydroxy, hydrogen, C.sub.1-8 substituted or unsubstituted thioalkyl, C.sub.6-10 substituted or unsubstituted thioaryl, 5 or 6 membered, substituted or unsubstituted thioheteroaryl; and a process for their synthesis through novel spirocyclic 4-amido azetidinones are disclosed.
    Type: Grant
    Filed: July 9, 1991
    Date of Patent: February 2, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Mark L. Greenlee, Thomas N. Salzmann, Frank P. DiNinno
  • Monofluorophosphate for calcium carbonate scale control and iron and manganese stabilization
    Patent number: 5182028
    Abstract: Monofluorophosphate salts, especially sodium monofluorophosphate (Na.sub.2 PO.sub.3 F), when added to various industrial water systems in concentrations between 0.1 mg/L and 50 mg/L, significantly reduce the amount of calcium carbonate scale which is formed on heat exchange and other metallic surfaces of such systems.Monofluorophosphate salts, especially sodium monofluorophosphate, when added to various water systems in concentrations between 0.1 mg/L and 50 mg/L also stabilizes soluble manganese ion and its reaction products, i.e., primarily MnO.sub.2, in desirable forms and reduced particle sizes.Monofluorophosphate salts, especially sodium monofluorophosphate, when added to various water systems in concentrations between 1 mg/L and 500 mg/L also stabilizes soluble iron ion and its reaction products, i.e., primarily Fe.sub.2 O.sub.3.
    Type: Grant
    Filed: March 28, 1991
    Date of Patent: January 26, 1993
    Assignee: Calgon Corporation
    Inventors: Bennett P. Boffardi, Ann M. Sherbondy
  • 2-biphenyl-carbapenems intermediates
    Patent number: 5182385
    Abstract: Carbapenems of the formula: ##STR1## are useful intermediates to antibacterial agents.
    Type: Grant
    Filed: October 9, 1990
    Date of Patent: January 26, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Frank P. Dininno, Thomas N. Salzmann
  • 2-benzocoumarinyl carbapenems
    Patent number: 5182384
    Abstract: Carbapenems of the formula ##STR1## are useful intermediates to antibacterial agents.
    Type: Grant
    Filed: May 24, 1991
    Date of Patent: January 26, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Frank DiNinno, Thomas A. Rano, Mark L. Greenlee
  • Medicinal use of certain tetrazolium salts
    Patent number: 5177092
    Abstract: Azole compounds including azoles and azolium salts, and their use as transglutaminase inhibitors are disclosed.
    Type: Grant
    Filed: June 17, 1991
    Date of Patent: January 5, 1993
    Assignee: Merck & Co., Inc.
    Inventors: David C. Remy, John J. Baldwin, David A. Claremon, Stella W. King
  • 2-phenanthrenyl-carbapenems
    Patent number: 5177202
    Abstract: Carbapenems of the formula ##STR1## are useful intermediates to antibacterial agents.
    Type: Grant
    Filed: October 9, 1990
    Date of Patent: January 5, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Frank P. Dininno, Mark L. Greenlee, Thomas N. Salzmann
  • Method for the control of pneumocystis carinii
    Patent number: 5166135
    Abstract: A method for the treatment of Pneumocystis carinii, the causative agent of pneumonia of particular severity to immune compromised patients such as those with acquired immune deficiency syndrome (AIDS), by administering a lipophilic cyclohexapeptide compound of the general formula ##STR1## wherein the R groups are fully defined in the text, is described. Compositions suitable for the treatment of P. carinii are also disclosed.
    Type: Grant
    Filed: August 9, 1991
    Date of Patent: November 24, 1992
    Assignee: Merck & Company, Inc.
    Inventor: Dennis M. Schmatz
  • Antifungal agent
    Patent number: 5164375
    Abstract: A phospholipid having the formula ##STR1## is described. The compound has antifungal properties.
    Type: Grant
    Filed: September 27, 1991
    Date of Patent: November 17, 1992
    Assignee: Merck & Company, Inc.
    Inventors: Frank VanMiddlesworth, Kenneth E. Wilson, Otto D. Hensens, Deborah Zink, Maria B. Lopez
  • Animal growth promotion
    Patent number: 5162337
    Abstract: Female prenatal, neonatal and postnatal animals are treated with compositions containing steroid biosynthesis inhibitors or antagonists which prevents the conversion of androgens to estrogens. The compositions are useful for improving growth and feed efficiency.
    Type: Grant
    Filed: October 5, 1990
    Date of Patent: November 10, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Alexander Elbrecht, Yi-Tien Yang, Roy G. Smith
  • 2-benzocoumarinyl carbapenems
    Patent number: 5162314
    Abstract: Carbapenems of the formula ##STR1## with E as ##STR2## are useful antibacterial agents.
    Type: Grant
    Filed: May 24, 1991
    Date of Patent: November 10, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Frank DiNinno, Mark L. Greenlee, Thomas A. Rano
  • 2-phenanthridonyl carbapenems having cationizeable substituents
    Patent number: 5157033
    Abstract: Carbapenems of the formula ##STR1## are useful antibacterial agents.
    Type: Grant
    Filed: April 16, 1991
    Date of Patent: October 20, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Frank DiNinno, Mark L. Greenlee, Thomas A. Rano
  • Imidazole compounds in compositions and methods in thrombolytic therapy
    Patent number: 5152988
    Abstract: The use of imidazoles of the formula ##STR1## and imidazolium salts of the formula ##STR2## in thromobolytic therapy are described.
    Type: Grant
    Filed: February 20, 1991
    Date of Patent: October 6, 1992
    Assignee: Merck & Co., Inc.
    Inventors: David A. Claremon, David C. Remy, John J. Baldwin
  • 2-phenanthridonyl carbapenems
    Patent number: 5153185
    Abstract: Carbapenems of the formula ##STR1## are useful antibacterial agents.
    Type: Grant
    Filed: April 16, 1991
    Date of Patent: October 6, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Frank DiNinno, Mark L. Greenlee, Thomas A. Rano
  • 2-benzocoumarinyl-carbapenems
    Patent number: 5153186
    Abstract: Carbapenems of the formula ##STR1## are useful antibacterial agents.
    Type: Grant
    Filed: May 24, 1991
    Date of Patent: October 6, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Frank DiNinno, Thomas A. Rano, Mark L. Greenlee